Mads Laustsen
Direttore/Membro del Consiglio presso NANOFORM FINLAND OYJ
Relazioni attive
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Andreas Hougaard Laustsen | M | - |
Bactolife A/S
 Bactolife A/S BiotechnologyHealth Technology Bactolife A/S is a Danish industrial biotech company that specializes in developing biological solutions to strengthen the gut microbiome and combat antimicrobial resistance. Bactolife is based in Kongens Lyngby, Denmark and was founded in 2017 by Andreas Hougaard Laustsen, Per Falholt, Mads Laustsen, David Kauffmann, and Sandra Wingaard Thrane. The company has approximately 40 employees and uses its proprietary binding protein technology to select and produce binding proteins that act on toxins without targeting growth or killing bacteria directly. Bactolife is developing and marketing ingredients for various groups, including mothers and children, the elderly, immunodeficient individuals, travelers, deployed individuals, and animal health. The company has proof of concept for its technology, including its most advanced animal health product, ablacto+, which stabilizes the gut of piglets and reduces the severity of post-weaning diarrhea. Mads Laustsen has been the CEO since 2017.
VenomAid Diagnostics ApS
 VenomAid Diagnostics ApS Medical/Nursing ServicesHealth Services VenomAid Diagnostics ApS provides diagnostic test services for snake bites. The company is based in Kongens Lyngby, Denmark. The Danish company was founded by Cecilie Knudsen, Søren H. Dam, Jonas A. Jürgensen, Andreas Hougaard Laustsen. Jonas A. Jürgensen has been the CEO since incorporation. | 7 anni |
| Miguel Laustsen de Oliveira Barreiros Calado | M | 68 | 5 anni | |
| Per Falholt | M | 65 |
Bactolife A/S
Bactolife A/S BiotechnologyHealth Technology Bactolife A/S is a Danish industrial biotech company that specializes in developing biological solutions to strengthen the gut microbiome and combat antimicrobial resistance. Bactolife is based in Kongens Lyngby, Denmark and was founded in 2017 by Andreas Hougaard Laustsen, Per Falholt, Mads Laustsen, David Kauffmann, and Sandra Wingaard Thrane. The company has approximately 40 employees and uses its proprietary binding protein technology to select and produce binding proteins that act on toxins without targeting growth or killing bacteria directly. Bactolife is developing and marketing ingredients for various groups, including mothers and children, the elderly, immunodeficient individuals, travelers, deployed individuals, and animal health. The company has proof of concept for its technology, including its most advanced animal health product, ablacto+, which stabilizes the gut of piglets and reduces the severity of post-weaning diarrhea. Mads Laustsen has been the CEO since 2017.
Novozymes A/S
 Novozymes A/S Chemicals: SpecialtyProcess Industries Novozymes A/S engages in the research and development of biotechnology solutions, which produces industrial enzymes and microorganisms. Its business areas include agriculture, bioenergy, biopharma, food and beverage, household care, leather, pulp and paper, textile and wastewater solutions. The company was founded in 2000 and is headquartered in Copenhagen, Denmark. | 24 anni |
| Jonas Jürgensen | M | - |
VenomAid Diagnostics ApS
VenomAid Diagnostics ApS Medical/Nursing ServicesHealth Services VenomAid Diagnostics ApS provides diagnostic test services for snake bites. The company is based in Kongens Lyngby, Denmark. The Danish company was founded by Cecilie Knudsen, Søren H. Dam, Jonas A. Jürgensen, Andreas Hougaard Laustsen. Jonas A. Jürgensen has been the CEO since incorporation. | 6 anni |
| Sandra Wingaard Thrane | M | - |
Bactolife A/S
Bactolife A/S BiotechnologyHealth Technology Bactolife A/S is a Danish industrial biotech company that specializes in developing biological solutions to strengthen the gut microbiome and combat antimicrobial resistance. Bactolife is based in Kongens Lyngby, Denmark and was founded in 2017 by Andreas Hougaard Laustsen, Per Falholt, Mads Laustsen, David Kauffmann, and Sandra Wingaard Thrane. The company has approximately 40 employees and uses its proprietary binding protein technology to select and produce binding proteins that act on toxins without targeting growth or killing bacteria directly. Bactolife is developing and marketing ingredients for various groups, including mothers and children, the elderly, immunodeficient individuals, travelers, deployed individuals, and animal health. The company has proof of concept for its technology, including its most advanced animal health product, ablacto+, which stabilizes the gut of piglets and reduces the severity of post-weaning diarrhea. Mads Laustsen has been the CEO since 2017. | 7 anni |
| David Kauffmann | M | - |
Bactolife A/S
Bactolife A/S BiotechnologyHealth Technology Bactolife A/S is a Danish industrial biotech company that specializes in developing biological solutions to strengthen the gut microbiome and combat antimicrobial resistance. Bactolife is based in Kongens Lyngby, Denmark and was founded in 2017 by Andreas Hougaard Laustsen, Per Falholt, Mads Laustsen, David Kauffmann, and Sandra Wingaard Thrane. The company has approximately 40 employees and uses its proprietary binding protein technology to select and produce binding proteins that act on toxins without targeting growth or killing bacteria directly. Bactolife is developing and marketing ingredients for various groups, including mothers and children, the elderly, immunodeficient individuals, travelers, deployed individuals, and animal health. The company has proof of concept for its technology, including its most advanced animal health product, ablacto+, which stabilizes the gut of piglets and reduces the severity of post-weaning diarrhea. Mads Laustsen has been the CEO since 2017. | 7 anni |
| Edward Hæggström | M | 55 | 9 anni | |
| Jeanne A. Thoma | F | 64 | 3 anni | |
| Karin Garre | M | 67 |
Symphogen A/S
 Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark. | 6 anni |
| Albert Häggström | M | 53 | 9 anni | |
| John Sørensen Haurum | M | 61 |
Synklino ApS
 Synklino ApS Medical/Nursing ServicesHealth Services Synklino ApS is a Danish biotech company that focuses on developing innovative therapies against virus infections. The company's first-in-class drug candidate, Syn002, targets cytomegalovirus infection in transplantation patients and aims to change the current antiviral treatment paradigm. Synklino is owned by renowned Nordic funds and institutional investors, including Eir Ventures, the Danish Growth Fund, and PKA, as well as approximately 70 private shareholders. The company is a spinout from the University of Copenhagen and the Technical University of Denmark and is incubated at the BioInnovation Institute in its prestigious Creation House program. | - |
| Cecilie Knudsen | F | - |
VenomAid Diagnostics ApS
VenomAid Diagnostics ApS Medical/Nursing ServicesHealth Services VenomAid Diagnostics ApS provides diagnostic test services for snake bites. The company is based in Kongens Lyngby, Denmark. The Danish company was founded by Cecilie Knudsen, Søren H. Dam, Jonas A. Jürgensen, Andreas Hougaard Laustsen. Jonas A. Jürgensen has been the CEO since incorporation. | 6 anni |
| Christian Jones | M | 44 | 6 anni | |
| David Rowe | M | 57 | 5 anni | |
| Henri von Haartman | M | - | 5 anni | |
| Peter Hänninen | M | 36 | 4 anni | |
| Anders Peter Gram | M | - |
Bactolife A/S
Bactolife A/S BiotechnologyHealth Technology Bactolife A/S is a Danish industrial biotech company that specializes in developing biological solutions to strengthen the gut microbiome and combat antimicrobial resistance. Bactolife is based in Kongens Lyngby, Denmark and was founded in 2017 by Andreas Hougaard Laustsen, Per Falholt, Mads Laustsen, David Kauffmann, and Sandra Wingaard Thrane. The company has approximately 40 employees and uses its proprietary binding protein technology to select and produce binding proteins that act on toxins without targeting growth or killing bacteria directly. Bactolife is developing and marketing ingredients for various groups, including mothers and children, the elderly, immunodeficient individuals, travelers, deployed individuals, and animal health. The company has proof of concept for its technology, including its most advanced animal health product, ablacto+, which stabilizes the gut of piglets and reduces the severity of post-weaning diarrhea. Mads Laustsen has been the CEO since 2017. | 3 anni |
| Antonio da Silva | M | 50 | 5 anni |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Peder Holk Nielsen | M | 67 |
Novozymes A/S
Novozymes A/S Chemicals: SpecialtyProcess Industries Novozymes A/S engages in the research and development of biotechnology solutions, which produces industrial enzymes and microorganisms. Its business areas include agriculture, bioenergy, biopharma, food and beverage, household care, leather, pulp and paper, textile and wastewater solutions. The company was founded in 2000 and is headquartered in Copenhagen, Denmark. | 20 anni |
| Benny Dalgaard Loft | M | 59 |
Novozymes A/S
Novozymes A/S Chemicals: SpecialtyProcess Industries Novozymes A/S engages in the research and development of biotechnology solutions, which produces industrial enzymes and microorganisms. Its business areas include agriculture, bioenergy, biopharma, food and beverage, household care, leather, pulp and paper, textile and wastewater solutions. The company was founded in 2000 and is headquartered in Copenhagen, Denmark. | 17 anni |
| Anders Lund | M | 51 |
Novozymes A/S
Novozymes A/S Chemicals: SpecialtyProcess Industries Novozymes A/S engages in the research and development of biotechnology solutions, which produces industrial enzymes and microorganisms. Its business areas include agriculture, bioenergy, biopharma, food and beverage, household care, leather, pulp and paper, textile and wastewater solutions. The company was founded in 2000 and is headquartered in Copenhagen, Denmark. | - |
| Rasmus Gottberg | M | - |
Novozymes A/S
Novozymes A/S Chemicals: SpecialtyProcess Industries Novozymes A/S engages in the research and development of biotechnology solutions, which produces industrial enzymes and microorganisms. Its business areas include agriculture, bioenergy, biopharma, food and beverage, household care, leather, pulp and paper, textile and wastewater solutions. The company was founded in 2000 and is headquartered in Copenhagen, Denmark. | 21 anni |
| Steen Riisgaard | M | 73 |
Novozymes A/S
Novozymes A/S Chemicals: SpecialtyProcess Industries Novozymes A/S engages in the research and development of biotechnology solutions, which produces industrial enzymes and microorganisms. Its business areas include agriculture, bioenergy, biopharma, food and beverage, household care, leather, pulp and paper, textile and wastewater solutions. The company was founded in 2000 and is headquartered in Copenhagen, Denmark. | 13 anni |
| Kirsten Drejer | M | 68 |
Symphogen A/S
Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark. | 16 anni |
| Torsten Kolind | M | - |
Novozymes A/S
Novozymes A/S Chemicals: SpecialtyProcess Industries Novozymes A/S engages in the research and development of biotechnology solutions, which produces industrial enzymes and microorganisms. Its business areas include agriculture, bioenergy, biopharma, food and beverage, household care, leather, pulp and paper, textile and wastewater solutions. The company was founded in 2000 and is headquartered in Copenhagen, Denmark. | - |
| Ulla Morin | F | 70 |
Novozymes A/S
Novozymes A/S Chemicals: SpecialtyProcess Industries Novozymes A/S engages in the research and development of biotechnology solutions, which produces industrial enzymes and microorganisms. Its business areas include agriculture, bioenergy, biopharma, food and beverage, household care, leather, pulp and paper, textile and wastewater solutions. The company was founded in 2000 and is headquartered in Copenhagen, Denmark. | 12 anni |
| Paul Petter Aas | M | 78 |
Novozymes A/S
Novozymes A/S Chemicals: SpecialtyProcess Industries Novozymes A/S engages in the research and development of biotechnology solutions, which produces industrial enzymes and microorganisms. Its business areas include agriculture, bioenergy, biopharma, food and beverage, household care, leather, pulp and paper, textile and wastewater solutions. The company was founded in 2000 and is headquartered in Copenhagen, Denmark. | 12 anni |
| Erik Gormsen | M | - |
Novozymes A/S
Novozymes A/S Chemicals: SpecialtyProcess Industries Novozymes A/S engages in the research and development of biotechnology solutions, which produces industrial enzymes and microorganisms. Its business areas include agriculture, bioenergy, biopharma, food and beverage, household care, leather, pulp and paper, textile and wastewater solutions. The company was founded in 2000 and is headquartered in Copenhagen, Denmark. | 21 anni |
| Rasmus von Gottberg | M | - |
Novozymes A/S
Novozymes A/S Chemicals: SpecialtyProcess Industries Novozymes A/S engages in the research and development of biotechnology solutions, which produces industrial enzymes and microorganisms. Its business areas include agriculture, bioenergy, biopharma, food and beverage, household care, leather, pulp and paper, textile and wastewater solutions. The company was founded in 2000 and is headquartered in Copenhagen, Denmark. | 21 anni |
| Jerker Gustav Hartwall | M | 54 |
Novozymes A/S
Novozymes A/S Chemicals: SpecialtyProcess Industries Novozymes A/S engages in the research and development of biotechnology solutions, which produces industrial enzymes and microorganisms. Its business areas include agriculture, bioenergy, biopharma, food and beverage, household care, leather, pulp and paper, textile and wastewater solutions. The company was founded in 2000 and is headquartered in Copenhagen, Denmark. | 11 anni |
| Bernhard R. M. Ehmer | M | 69 |
Symphogen A/S
Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark. | 2 anni |
| Per Olesen | M | - |
Novozymes A/S
Novozymes A/S Chemicals: SpecialtyProcess Industries Novozymes A/S engages in the research and development of biotechnology solutions, which produces industrial enzymes and microorganisms. Its business areas include agriculture, bioenergy, biopharma, food and beverage, household care, leather, pulp and paper, textile and wastewater solutions. The company was founded in 2000 and is headquartered in Copenhagen, Denmark. | 20 anni |
| Nina Herne | M | 55 |
Novozymes A/S
Novozymes A/S Chemicals: SpecialtyProcess Industries Novozymes A/S engages in the research and development of biotechnology solutions, which produces industrial enzymes and microorganisms. Its business areas include agriculture, bioenergy, biopharma, food and beverage, household care, leather, pulp and paper, textile and wastewater solutions. The company was founded in 2000 and is headquartered in Copenhagen, Denmark. | 1 anni |
| Christoffer Søderberg | M | - |
Symphogen A/S
Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark. | - |
| Gonçalo Nuno N. da Silva Rebelo de Andrade | M | - | - | |
| Niklas Sandler | M | 52 | 4 anni | |
| Johanna Tuomisto | F | 58 | 2 anni | |
| Marianne Weile Nonboe | F | 64 |
Novozymes A/S
Novozymes A/S Chemicals: SpecialtyProcess Industries Novozymes A/S engages in the research and development of biotechnology solutions, which produces industrial enzymes and microorganisms. Its business areas include agriculture, bioenergy, biopharma, food and beverage, household care, leather, pulp and paper, textile and wastewater solutions. The company was founded in 2000 and is headquartered in Copenhagen, Denmark. | - |
| Ronald Eastman | M | 71 |
Symphogen A/S
Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark. | - |
| Cynthia Flowers | F | 64 | - | |
| Mads Krogsgaard Thomsen | M | 63 |
Symphogen A/S
Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark. | - |
| James R. Piggott | M | 69 |
ZymoGenetics, Inc.
 ZymoGenetics, Inc. Pharmaceuticals: MajorHealth Technology ZymoGenetics, Inc. develops protein based drugs. It focuses on the discovery, development, manufacture, and commercialization of therapeutic proteins for the treatment of human diseases, including homeostasis, inflammatory and autoimmune diseases, cancer, and viral infections. The company was founded by Earl W. Davie, Benjamin D. Hall and Michael Smith in 1981 and is headquartered in Seattle, WA. | 9 anni |
| Gregory D. Phelps | M | 75 |
ZymoGenetics, Inc.
ZymoGenetics, Inc. Pharmaceuticals: MajorHealth Technology ZymoGenetics, Inc. develops protein based drugs. It focuses on the discovery, development, manufacture, and commercialization of therapeutic proteins for the treatment of human diseases, including homeostasis, inflammatory and autoimmune diseases, cancer, and viral infections. The company was founded by Earl W. Davie, Benjamin D. Hall and Michael Smith in 1981 and is headquartered in Seattle, WA. | 2 anni |
| Kurt Anker Nielsen | M | 78 |
Novozymes A/S
Novozymes A/S Chemicals: SpecialtyProcess Industries Novozymes A/S engages in the research and development of biotechnology solutions, which produces industrial enzymes and microorganisms. Its business areas include agriculture, bioenergy, biopharma, food and beverage, household care, leather, pulp and paper, textile and wastewater solutions. The company was founded in 2000 and is headquartered in Copenhagen, Denmark. | - |
| Peter Helt Jacobsen Haahr | M | 56 |
Symphogen A/S
Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark. | - |
| Walther Thygesen | M | 74 |
Novozymes A/S
Novozymes A/S Chemicals: SpecialtyProcess Industries Novozymes A/S engages in the research and development of biotechnology solutions, which produces industrial enzymes and microorganisms. Its business areas include agriculture, bioenergy, biopharma, food and beverage, household care, leather, pulp and paper, textile and wastewater solutions. The company was founded in 2000 and is headquartered in Copenhagen, Denmark. | 11 anni |
| Lise Kingo | F | 62 |
Novozymes A/S
Novozymes A/S Chemicals: SpecialtyProcess Industries Novozymes A/S engages in the research and development of biotechnology solutions, which produces industrial enzymes and microorganisms. Its business areas include agriculture, bioenergy, biopharma, food and beverage, household care, leather, pulp and paper, textile and wastewater solutions. The company was founded in 2000 and is headquartered in Copenhagen, Denmark. | 11 anni |
| Göran Albert Ando | M | 75 |
Symphogen A/S
Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark. | - |
| Jeffrey H. Buchalter | M | 67 |
Symphogen A/S
Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark. | - |
| Søren Lemonius | M | 59 |
Symphogen A/S
Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark. | - |
| Martin Edwards | M | 68 |
ZymoGenetics, Inc.
ZymoGenetics, Inc. Pharmaceuticals: MajorHealth Technology ZymoGenetics, Inc. develops protein based drugs. It focuses on the discovery, development, manufacture, and commercialization of therapeutic proteins for the treatment of human diseases, including homeostasis, inflammatory and autoimmune diseases, cancer, and viral infections. The company was founded by Earl W. Davie, Benjamin D. Hall and Michael Smith in 1981 and is headquartered in Seattle, WA. | 3 anni |
| Glenn H. Kawasaki | M | - |
ZymoGenetics, Inc.
ZymoGenetics, Inc. Pharmaceuticals: MajorHealth Technology ZymoGenetics, Inc. develops protein based drugs. It focuses on the discovery, development, manufacture, and commercialization of therapeutic proteins for the treatment of human diseases, including homeostasis, inflammatory and autoimmune diseases, cancer, and viral infections. The company was founded by Earl W. Davie, Benjamin D. Hall and Michael Smith in 1981 and is headquartered in Seattle, WA. | 4 anni |
| Jesper Preben Allentoft | M | 69 |
Novozymes A/S
Novozymes A/S Chemicals: SpecialtyProcess Industries Novozymes A/S engages in the research and development of biotechnology solutions, which produces industrial enzymes and microorganisms. Its business areas include agriculture, bioenergy, biopharma, food and beverage, household care, leather, pulp and paper, textile and wastewater solutions. The company was founded in 2000 and is headquartered in Copenhagen, Denmark. | 5 anni |
| Henrik Gürtler | M | 70 |
Novozymes A/S
Novozymes A/S Chemicals: SpecialtyProcess Industries Novozymes A/S engages in the research and development of biotechnology solutions, which produces industrial enzymes and microorganisms. Its business areas include agriculture, bioenergy, biopharma, food and beverage, household care, leather, pulp and paper, textile and wastewater solutions. The company was founded in 2000 and is headquartered in Copenhagen, Denmark. | - |
| Thomas Geza Solyom Nagy | M | 60 |
Novozymes A/S
Novozymes A/S Chemicals: SpecialtyProcess Industries Novozymes A/S engages in the research and development of biotechnology solutions, which produces industrial enzymes and microorganisms. Its business areas include agriculture, bioenergy, biopharma, food and beverage, household care, leather, pulp and paper, textile and wastewater solutions. The company was founded in 2000 and is headquartered in Copenhagen, Denmark. | - |
| Erik Laursen | M | - |
ZymoGenetics, Inc.
ZymoGenetics, Inc. Pharmaceuticals: MajorHealth Technology ZymoGenetics, Inc. develops protein based drugs. It focuses on the discovery, development, manufacture, and commercialization of therapeutic proteins for the treatment of human diseases, including homeostasis, inflammatory and autoimmune diseases, cancer, and viral infections. The company was founded by Earl W. Davie, Benjamin D. Hall and Michael Smith in 1981 and is headquartered in Seattle, WA. | 8 anni |
Statistiche
| Paese | Relazioni | % del totale |
|---|---|---|
| Danimarca | 38 | 67.86% |
| Finlandia | 13 | 23.21% |
| Stati Uniti | 5 | 8.93% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Mads Laustsen
- Contatti personali